Related Experiment Videos
Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction
P Søgaard1, C O Gøtzsche, J Ravkilde
1Department of Medicine and Cardiology, Aarhus University Hospital, Denmark.
Insights
Captopril treatment improved cardiac function in patients post-myocardial infarction. It reduced ischemic burden, enhanced exercise capacity, and prevented left ventricular dilation, improving overall heart health.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin converting enzyme inhibitors (ACE inhibitors) benefit heart failure and myocardial infarction patients.
- ACE inhibitors show positive effects on ischemic myocardium in experimental studies.
Purpose of the Study:
- To evaluate the effects of captopril on left ventricular dysfunction after myocardial infarction.
- To assess captopril's impact on ischemic burden, working capacity, and ventricular remodeling.
Main Methods:
- A 6-month, double-blind, placebo-controlled study involving 64 patients with post-myocardial infarction left ventricular dysfunction.
- Patients received either placebo or captopril (50 mg daily).
- Evaluations included ambulatory ECG, bicycle ergometer testing, and echocardiography.
Main Results:
- Captopril significantly reduced ST segment depression duration and exercise-induced ST depression compared to placebo.
- Working capacity increased significantly in the captopril group and was higher than placebo at study end.
- Captopril prevented left ventricular dilation and reduced end-systolic volume, unlike the placebo group.
Conclusions:
- Captopril favorably impacts post-myocardial infarction dysfunctioning myocardium.
- It reduces ischemic burden, increases working capacity, and prevents left ventricular dilation.
- Captopril improves systolic function in patients after myocardial infarction.
Background:
Treatment with angiotensin converting enzyme inhibitors has been shown to be beneficial in patients with heart failure and myocardial infarction. Experimental studies have shown beneficial effects on the ischemic myocardium.
Methods And Results:
The effects of captopril were evaluated in 64 patients with left ventricular dysfunction after myocardial infarction. The patients were randomized at day 7 to either placebo or captopril (50 mg daily) in a double-blind parallel study over a period of 6 months. The patients were followed up by means of ambulatory ECG monitoring, bicycle ergometer testing, and echocardiographic examination. The duration of ST segment depression detected during ambulatory ECG monitoring was lower in the captopril group (87 minutes) than in the placebo group (638 minutes) (p < 0.001), and the number of patients in the captopril group with exercise-induced ST segment depression (p < 0.01) was lower at the completion of the study. The working capacity increased during the study period from 540 +/- 47 seconds to 738 +/- 41 seconds (p < 0.01) in the captopril group and was higher than that in the placebo group (530 +/- 43 seconds, p < 0.01) at the end of the study. Furthermore, a significant dilation of the left ventricular end-diastolic and end-systolic volumes was observed in the placebo group (p < 0.05); this was prevented in the captopril group where, in addition, a reduction in end-systolic volume was observed (p < 0.05).
Conclusions:
Captopril has a favorable effect on the dysfunctioning myocardium after myocardial infarction inasmuch as the ischemic burden is reduced, the working capacity is increased, dilation of the left ventricle is prevented, and systolic function is improved.